Clinical trials: FAPI
Thyroid Pathology, Head and Neck Cancer (H&N)
FAPI PET Imaging - An Exploratory Study
This study is testing a new imaging tracer called [18F]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions…
- Conditions
- Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis
- Trial name
- FAPIPET (NCT07705074)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 5 sites in Switzerland
- Volunteers
- 770 people
- Sponsor
- Martin Huellner
Advanced Pancreatic Cancer and Cholangiocarcinoma
A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors
This study is a prospective, single-center, open, single-arm, exploratory study to evaluate the safety and efficacy of 177Lu-EB-FAPI PRRT, and to explore 177Lu-EB-FAPI in patients with advanced pancreatic cancer and…
- Trial name
- CISPD-5 (NCT06081322)
- Testing
- PRRT with 177Lu-EB-FAPI
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Zhejiang University
High Grade Serous Ovarian Cancer (HGSOC)
68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study
The investigator will use a technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan.
- Trial name
- FAST HOC (NCT05956093)
- Testing
- FAPI PET CT
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer
68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic Cancer
This is a preliminary study of 68Ga-FAPI-FS PET/CT or PET/MR in patients with confirmed or suspicious pancreatic cancer. The goal is to determine the safety, biodistribution, and tumor uptake of 68Ga-FAPI-FS.
- Trial name
- NCT05875753
- Testing
- 68Ga-FAPI-FS PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Sarcoma
Paediatric Sarcoma, Hybrid Imaging & FAPI - Raising the Diagnostic Standard for Paediatric Sarcoma Patients, Combining Novel Radiotracer FAPI and Whole-body PET/MRI
The goal of this clinical trial is to evaluate [68Ga]FAPI-46 whole-body PET/MRI as a diagnostic tool to improve tumour lesion examination at primary staging, during treatment control and at relapse in paediatric sarcoma patients.
- Trial name
- PsiFI (NCT07861217)
- Testing
- FAPI tracer
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cardiovascular Diseases (CVD)
Clinical Research on 68Ga-FAPI PET/CMR in Cardiovascular Diseases
FAP-targeted PET imaging using 68Ga-FAPI enables early detection of myocardial fibrosis. Combined PET/CMR provides comprehensive cardiac assessment without extra radiation.
- Trial name
- NCT07063043
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai East Hospital
Gastric Cancer, Pancreatic Cancer
Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/CT in Patients With Gastrointestinal Tumors and Compared With 18F-FDG PET/CT
To evaluate the potential usefulness of 18F-AlF-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in gastrointestinal tumors, and compared with 18F-FDG PET/CT.
- Conditions
- Gastric Cancer, Pancreatic Cancer, Liver Cancer
- Trial name
- NCT05430841
- Testing
- 18F-FDG, 18F-AlF-FAPI PET/CT
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Myocardial Remodeling After AMI
Cardiac Fibroblast Activation Detected by 68Ga-FAPI PET/MR
Myocardial infarction is the most common cause of high mortality in the modern world. The short-term survival rate of ST-elevated myocardial infarction (STEMI) has been dramatically increased in the past decades thanks to primary…
- Trial name
- NCT04723953
- Testing
- 68Ga-FAPI PET/MRI
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Ruijin Hospital
Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD)
Unravelling Intestinal Fibrosis in Ulcerative Colitis
The main objectives are: (i) to identify candidate fibrotic cellular pathways in UC patients treated with a JAK inhibitor filgotinib), and (ii) to detect and monitor in vivo fibrosis in UC patients using FAPi-PET/CT imaging
- Conditions
- Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD), Fibroblast Activation Protein Inhibitor
- Trial name
- INTERACT (NCT06604273)
- Testing
- Fibroblast Activation Protein Inhibitor
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Rectal Cancer
A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer
The combination of short course radiotherapy and immunotherapy helps to increase the proportion of pathological complete response after neoadjuvant therapy, providing more patients with the opportunity for organ preservation.
- Trial name
- NCT06608537
- Testing
- neoadjuvant SCRT followed by Sintilimab plus CAPOX
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer Metastatic Disease, Prostate Cancers
Using FAPI PET/MRI to Evaluate Prostate Cancer
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue.
- Trial name
- NCT06675357
- Testing
- FAPI, Positron Emission Tomography (PET), Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Madison
Inflammatory Bowel Disease (IBD), Disease Activity
Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging
The goal of this observational study is to evaluate the role and effect of 18F-FAPI PET imaging in the identification of intestinal lesions and the assessment of disease activity in inflammatory bowel disease.
- Conditions
- Inflammatory Bowel Disease (IBD), Disease Activity, FAPI
- Trial name
- IBD，18F-FAPI (NCT06945549)
- Testing
- 18F-FAPI PET Imaging
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
177Lu-DOTA-FAPI, 68Ga-DOTA-FAPI
68Ga-DOTA-FAPI and 177Lu-DOTA-FAPI Theranostic Pair in Patients With Various Types of Cancer (Locally Advanced or Metastatic Cancer)
This is a Phase I, first-in-human study to evaluate the safety and efficacy of the 68Ga-DOTA-FAPI and 177Lu-DOTA-FAPI theranostic pair in patients with various types of cancer (locally advanced or metastatic cancer).
- Conditions
- 177Lu-DOTA-FAPI, 68Ga-DOTA-FAPI, Theranostic
- Trial name
- NCT04849247
- Testing
- 68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Enhanced CT, 18F-FDG PET/CT
Preoperative Abdominal Enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT in Peritoneal Carcinomatosis of Gastric Cancer
This study aims to explore the value of 68Ga-FAPI PET/CT in the diagnosis of gastric cancer peritoneal carcinomatosis in high-risk patients compared with conventional abdominal enhanced CT and 18F-FDG PET/CT.
- Conditions
- Enhanced CT, 18F-FDG PET/CT, 68Ga-FAPI PET/CT, Gastric Cancer
- Trial name
- NCT04778345
- Testing
- 68Ga-FAPI PET/CT scan
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Fujian Medical University
Refractory Solid Tumor
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
Increased fibroblast activation protein expression is positively correlated with the aggressiveness of cancer. Radiolabeled fibroblast activation protein inhibitor therapy, also known as radioligand therapy has become a novel…
- Trial name
- NCT05963386
- Testing
- 177Lu-DOTA-EB-FAPI radionuclide therapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Cholangiocarcinoma
The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
Background Bile duct cancer (cholangiocarcinoma) represents the second most common type of hepatobiliary cancer worldwide with an incidence of 0.35 to 2 per 100.000 annually.
- Trial name
- FAPIChol (NCT06355427)
- Testing
- [18F]F-FAPI PET-CT
- Where
- 3 sites in Netherlands
- Volunteers
- 81 people
- Sponsor
- Mara Veenstra, MD
Fibrosis Lung
Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis
The goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrotic lung tissue and how this information can be used to better diagnose…
- Trial name
- NCT06940427
- Testing
- FAPI tracer, PET/MRI
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Wisconsin, Madison
18F-FAPI, 18F-FDG
18F-FAPI PET Imaging in Pancreatic Adenocarcinoma
To explore the potential efficacy of 18F-FAPI-04 PET/CT for PDAC tumour staging and compare the results with those obtained using 18F-FDG PET/CT.
- Conditions
- 18F-FAPI, 18F-FDG, Pancreas Adenocarcinoma, Diagnosis
- Trial name
- NCT05884463
- Testing
- 18F-FAPI, 18F-FDG
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Zhejiang University
Cancer
Application of FAPI and FDG PET Imaging in Patients With Different Types of Cancer
Cancer associated fibroblasts (CAFs) can promote tumor cell proliferation, migration, invasion, and angiogenesis through immunosuppressive effects and the production of mediators, thereby promoting tumor growth and progression.
- Trial name
- NCT06284070
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Malignant Neoplasm
Comparing 18F-FAPI-04 and 18F-FDG PET/CT in Cancer Detection
Evaluating fluoro-18-fibroblast activation protein inhibitor-04 positron emission computed tomography's diagnostic efficacy for primary malignancies versus 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose.
- Trial name
- NCT06206642
- Testing
- PET/CT
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Lanzhou University Second Hospital